Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

IPIX Receives Data for Direct Inhibition of SARS-CoV-2,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
LilKahuna Member Profile
 
Followed By 249
Posts 20,638
Boards Moderated 1
Alias Born 10/03/04
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/14/2021 5:01:12 PM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/11/2021 7:00:00 AM
CEO's Presenting on the Emerging Growth Conference 17 TODAY.  Register Now InvestorsHub NewsWire - 9/29/2021 8:00:00 AM
CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61% Growth InvestorsHub NewsWire - 9/28/2021 7:24:31 AM
Nightfood, Inc. (OTCQB: NGTF) Significant Retail Expansion InvestorsHub NewsWire - 7/21/2021 6:47:54 AM
Innovation Pharma selected for a presentation on experimental COVID-19 therapy Seeking Alpha - 6/18/2021 10:31:54 AM
The Emerging Growth Conference is Today.  Register Now. InvestorsHub NewsWire - 6/9/2021 7:00:00 AM
Patient enrollment reaches 90 percent in Innovation Pharmaceuticals' mid-stage COVID-19 trial Seeking Alpha - 5/27/2021 10:29:46 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 8:01:45 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/3/2021 12:54:36 PM
Innovation gives update on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 4/5/2021 8:03:34 AM
CLS Holdings, (OTCQB: CLSH) $1.49 million Net Revenue for Feb Highest in Company History InvestorsHub NewsWire - 3/9/2021 6:37:33 AM
Innovation updates on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 3/5/2021 1:07:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/22/2021 11:20:39 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 2/17/2021 8:01:12 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/11/2021 4:47:49 PM
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/15/2021 12:36:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/22/2020 9:01:10 AM
Biotech Companies; Recent Milestones and Potential Upside InvestorsHub NewsWire - 12/22/2020 8:05:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/10/2020 6:03:50 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/16/2020 12:47:44 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2020 9:01:35 AM
Epazz, Inc. (OTC Pink: EPAZ) Adds Vaccine Management as part of COVID Compliance Features InvestorsHub NewsWire - 11/10/2020 6:48:57 AM
LilKahuna   Wednesday, 04/01/20 11:33:02 AM
Re: None
Post # of 379698 
IPIX Receives Data for Direct Inhibition of SARS-CoV-2,
the Novel Coronavirus Responsible for COVID-19


WAKEFIELD, MA – April 1, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today it has received data supporting Brilacidin’s direct inhibition of SARS-CoV-2, the novel coronavirus responsible for COVID-19. The testing of Brilacidin was conducted by researchers at one of the U.S. Regional Biocontainment Laboratories (RBLs). Few compounds have shown activity against SARS-CoV-2, as summarized in the article linked below.

Andersen P, et al. “Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents.” Int J Infect Dis. 2020 Feb 17;93:268-276. doi: 10.1016/j.ijid.2020.02.018.
https://www.sciencedirect.com/science/article/pii/S120197122030076X

https://ars.els-cdn.com/content/image/1-s2.0-S120197122030076X-gr5.jpg

VERO cells, a monkey kidney cell line commonly used to screen small molecule inhibitors of viruses, were used to test whether Brilacidin inhibits SARS-CoV-2. Cells were pretreated with Brilacidin at increasing concentrations (at 2 µM and at 10 µM) for two hours prior to the infection. Cells treated with the vehicle alone (Dimethyl sulfoxide or DMSO) were maintained alongside, as controls. At 16 hours post-infection (16hpi), researchers observed a dose-dependent reduction in the SARS-CoV-2 infectious viral titers from the Brilacidin treated cells as compared to the vehicle-alone control, as shown below. (The higher number of asterisks denote higher statistical significance compared to control.)

RBL Figure 1
The Company is reviewing data received yesterday and anticipates more data will be forthcoming. Following discussions with researchers at the RBL, the Company will provide additional information and insight into possible joint research plans going forward. It is management’s understanding that few compounds advance to this next stage of SARS-CoV-2 research.

In a broader context, demonstration of Brilacidin’s direct antiviral activity against the SARS-CoV-2 virus supports the drug’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications. Additional data, based on successfully completed Phase 2 clinical studies in other clinical indications, using various modes of administration, show Brilacidin’s ability to inhibit interleukin-6 (IL-6) and other pro-inflammatory cytokines and chemokines, identified as central drivers in the worsening prognoses of COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help fight secondary bacterial infections, which can co-present in patients with COVID-19

* Never borrow to invest.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences